Author

E. Leucci

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:gene regulatory network inference· 2 Research Focus:differential expression· 1

Frequent Co-Authors

J.-C. Marine· 4 shared O. Bechter· 4 shared J. Pozniak· 3 shared P. Karras· 3 shared S. Cinque· 3 shared D. Lambrechts· 2 shared D. Pedri· 2 shared E. Demesmaeker· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J.-C. Marine

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

The assembly of cancer-specific ribosomes by the lncRNA LISRR suppresses melanoma anti-tumour immunity

S. Cinque, Y. Verheyden, S. Adnane, A. Marino, V. Katopodi, E. Demesmaeker, Z. Knezevic, S. Hanache, R. Vendramin, A. Cuomo, J. Pozniak, A. C. Calabuig, S. Tabruyn, O. Bechter, M. F. Baietti, , E. Leucci

This study identifies LISRR, a cancer-specific lncRNA that assembles immunosuppressive ribosomes in melanoma, suppressing anti-tumour immunity and resistance to immune checkpoint blockade.

bioRxiv · Jan 6, 2023 · PreprintCancer Biology

A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanoma

J. Pozniak, D. Pedri, E. Landeloos, Y. Van Herck, A. Antoranz, P. Karras, A. Nowosad, S. Makhzami, G. Bervoets, M. Dewaele, L. Vanwynsberghe, S. Cinque, S. Kint, K. Vandereyken, T. Voet, , J.-C. Marine

This study identifies a TCF4/BRD4-dependent regulatory network that drives cross-resistance to ICB and targeted therapy in melanoma by analyzing scRNA-seq data from a longitudinal cohort.

bioRxiv · Aug 11, 2022 · PreprintCancer Biology

The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival

S. Dewaele, L. Delhaye, B. De Paepe, E. De Bony, J. De Wilde, K. Vanderheyden, J. Anckaert, N. Yigit, E. VandenEynde, F. Nemati, D. Decaudin, A. Jochemsen, E. Leucci, J. Vandesompele, J. Van Dorpe, , P. Mestdagh

This study shows that inhibiting the lncRNA SAMMSON reduces uveal melanoma cell growth and viability by impairing mitochondrial function and protein translation.

bioRxiv · Jan 18, 2021Cancer Biology

A neural crest stem cell-like state drives nongenetic resistance to targeted therapy in melanoma

O. Marin-Bejar, A. Rogiers, M. Dewaele, J. Femel, P. Karras, J. Pozniak, G. Bervoets, N. Van Raemdonck, D. Pedri, T. Swings, J. Demeulemeester, S. Vander Borght, F. Bosisio, J. J. van den Oord, I. Vanden Bempt, , J.-C. Marine

This study identifies a neural crest stem cell-like state in melanoma minimal residual disease that drives nongenetic resistance to MAPK-targeted therapy and shows that targeting FAK/SRC signaling can delay relapse.

bioRxiv · Dec 15, 2020 · PreprintCancer Biology

Activation of the Integrated Stress Response in drug-tolerant melanoma cells confers vulnerability to mitoribosome-targeting antibiotics.

R. Vendramin, A. Konnova, S. Adnane, S. Cinque, V. Katopodi, Z. Knezevic, P. Karras, E. Demesmaeker, F. M. Bosisio, L. Rizzotto, O. Bechter, J.-C. Marine, E. Leucci

This study shows that activating the Integrated Stress Response in drug-tolerant melanoma cells makes them vulnerable to mitoribosome-targeting antibiotics, offering a new therapeutic strategy.

bioRxiv · Jun 26, 2020Cancer Biology